Form 4: Viridian Therapeutics Director Sarah Gheuens Granted 21,000 Stock Options

Viridian Therapeutics, Inc. Director Sarah Gheuens was granted 21,000 stock options with an exercise price of $14.47, vesting by July 2026 or the 2026 annual meeting.

Summary

• Sarah Gheuens, a Director of Viridian Therapeutics, Inc. (VRDN), acquired 21,000 stock options.
• The stock options have an exercise price of $14.47 per share.
• The options were granted on July 1, 2025.
• The options vest in full upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders.
• Vesting is contingent on Ms. Gheuens' continued service on the Board of Directors.
• The stock options expire on July 1, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive sign of alignment between management/board and shareholder interests, incentivizing long-term performance. It's a routine compensation event, generally viewed favorably as it ties director compensation to stock performance.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedule encourages continued service and commitment from the director to the company's strategic objectives.

Negatives

• The future exercise of these stock options could lead to minor dilution of existing shares, although this is a standard aspect of equity compensation.

Risks

• The vesting of the 21,000 stock options is subject to the reporting person's continued service on the Board of Directors, meaning the options could be forfeited if service ceases before the vesting conditions are met.

Future Outlook

The vesting schedule for the stock options, tied to continued service through July 2026 or the 2026 annual meeting, indicates an expectation of the director's ongoing contribution to the company's governance and strategic direction.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is typical for this type of regulatory disclosure.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like Viridian Therapeutics, Inc., to attract and retain experienced board members and align their incentives with long-term shareholder value creation. This practice is consistent across many publicly traded companies, particularly those in growth-oriented sectors where equity compensation is a significant component of remuneration.

Comparison to Industry Standards

• The grant of 21,000 stock options to a director is within the typical range for non-executive director compensation in the biotech sector, though specific numbers vary widely based on company size, stage of development, and individual director responsibilities.
• An exercise price of $14.47, presumably the market price on the grant date, is standard for incentive stock options, ensuring the options have value only if the stock price appreciates.
• A 10-year expiration period (until July 1, 2035) is a common term for stock options, providing a long window for the options to become in-the-money.
• Vesting over approximately one year (by July 2026) or upon the next annual meeting is a common practice for director equity grants, encouraging continued board service.

Stakeholder Impact

• **Shareholders**: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases. However, potential future exercise could lead to minor dilution.
• **Employees**: No direct impact on employees mentioned.
• **Customers**: No direct impact on customers mentioned.
• **Suppliers**: No direct impact on suppliers mentioned.
• **Creditors**: No direct impact on creditors mentioned.

Next Steps

• The director, Sarah Gheuens, will continue her service on the Board of Directors of Viridian Therapeutics, Inc.
• The stock options will vest upon the earlier of July 1, 2026, or the Issuer's 2026 annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Viridian Therapeutics, VRDN, Stock Option, Director Compensation, SEC Form 4, Equity Grant, Insider Transaction, Sarah Gheuens